RSV hospitalizations were significantly higher than normal again last week amid a respiratory virus season that's hitting the United States earlier and harder than usual, according to new data ...

Infant protection against respiratory syncytial virus (RSV) by maternal RSV vaccination or receipt of RSV monoclonal antibody ...

The Public Health Department's improved dashboard includes data on real-time spread and vaccination rates for the three respiratory viruses.

A new study included data on 36,706 individuals who were hospitalized and 37,842 who visited the ED while exhibiting RSV-like illness. The vast majority of patients in each setting tested negative for ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case for its first-to-market respiratory syncytial virus (RSV) shot Arexvy. GSK on ...

Nirsevimab may offer infants stronger protection against severe respiratory syncytial virus than maternal vaccination, ...

This multi-state study is a real world data analyses of the effectiveness of the RSV -- short for respiratory syncytial virus -- vaccine. VISION Network researchers report that across the board these ...

During last year's respiratory virus season, newly approved vaccines for respiratory syncytial virus (RSV) were effective in preventing associated hospitalizations and more serious outcomes in adults ...

If your patient is pregnant or older than 60 years and due for a respiratory syncytial virus (RSV) shot, now’s the time to act. A major new review highlighted the vaccine’s impact and safety, ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...